This amplification leads to increased expression of PD-L1, PD-L2, and JAK2, enhancing the sensitivity of these lymphomas to immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, thereby offering significant therapeutic potential. The gene discussed is PDCD1; the disease is lymphoma.